Ledger.Open graph →
SEC Form D · filed October 7, 2020

Talaris Therapeutics, Inc

Offering
$115.0M
Sold
$115.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
LOUISVILLE, KY
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (14)

Geoff Mackay · Brookline, MADirectorFrancois Nader · Louisville, KYDirectorNick Galakatos · Cambridge, MADirectorScott Requadt · Cambridge, MAExec · DirectorFrancois Nader · Louisville, KYDirectorSandip Agarwala · Louisville, KYDirectorSuzanne Ildstad · Louisville, KYExec · DirectorMark Mcdade · Boston, MADirectorScott Requadt · Monmouth Junction, NJExec · DirectorNick Galakatos · Louisville, KYDirectorSuzanne Ildstad · Louisville, KYExec · DirectorSandip Agarwala · Louisville, KYDirectorGeoff Mackay · Brookline, MADirectorMark Mcdade · San Francisco, CADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗